Trial Profile
A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin; Gemcitabine
- Indications Tumours
- Focus Therapeutic Use
- Acronyms AGNOSTOS
- 25 Jan 2024 Status changed from recruiting to completed.
- 11 Oct 2016 Planned number of patients changed from 120 to 132.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.